Accumulation Stage Identifier and Strategy around for Trading
Audit verdict
No reliable edge found
Its average result can't be told apart from chance, so it stays out of our rankings. The script itself passed our repainting audit.
Audit details
How we decide whether a strategy enters our rankings. Read the methodology →
How its evidence compares
The t-statistic measures how far the average result sits from zero relative to its noise. Below about 2, it is within what random entries produce.
Best 5 of 214 backtests
Shown for transparency.
| Symbol | Timeframe | Net profit | Profit factor | Trades | Max drawdown |
|---|---|---|---|---|---|
iPath Series B S&P 500 VIX Short-Term Futures ETN AMEX:VXX | 4H | +234% | 1.20 | 28 | 76% |
iPath Series B S&P 500 VIX Short-Term Futures ETN AMEX:VXX | 2H | +51% | 1.07 | 77 | 108% |
U.S. Dollar/Japanese Yen FX:USDJPY | 1D | +38% | 1.24 | 118 | 23% |
Euro Fx/U.S. Dollar FX:EURUSD | 4H | +34% | 1.16 | 414 | 17% |
iPath Series B S&P 500 VIX Short-Term Futures ETN AMEX:VXX | 1H | +26% | 1.01 | 193 | 76% |
Is Accumulation Stage Identifier and Strategy around for Trading profitable?
Not reliably, based on our tests. Across 214 backtests, 0 of 9 with more than 15 trades pass our quality gate. The best result is +234% on iPath Series B S&P 500 VIX Short-Term Futures ETN (4H, 28 trades). On average, its results are statistically indistinguishable from chance (p = 0.54).
Strategies that passed our audit
Ranked strategies from the same family, ordered by robust score.
Explore the best Trading & TradingView strategies
Stop trading blindly. Explore quality-gated backtests and improve your trading skills with data.
Start for free